Rubius Therapeutics Inc (RUBY):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Rubius Therapeutics Inc (RUBY) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8156
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:30
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Rubius Therapeutics Inc (Rubius Therapeutics) is a biotechnology company that focuses on the development of medicines for the treatment of rare diseases, cancer and autoimmune diseases. The company through its rubius erythrocyte design (RED) platform engineer and culture Red Cell Therapeutics (RCT) product candidates. Its products under development are intended for the treatment of phenylketonuria, refractory gout, homocystinuria, hyperoxaluria, R/R aPD1 solid tumor, acute myeloid leukemia (AML) post-allogeneic hematopoietic stem cell transplantation, cancer, pemphigus vulgaris and type 1 diabetes, among others. Rubius Therapeutics is headquartered in Cambridge, Massachusetts, the US.

Rubius Therapeutics Inc (RUBY) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Rubius Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Rubius Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Rubius Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Rubius Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Rubius Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Rubius Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Rubius Therapeutics Raises USD100 Million in Venture Financing 10
Rubius Therapeutics Raises Funds through Venture Financing 11
Rubius Therapeutics Raises USD120 Million in Venture Financing 12
Rubius Therapeutics Raises USD25 Million in Venture Financing 13
Licensing Agreements 14
Rubius Therapeutics Enters into Licensing Agreement with Whitehead Institute for Biomedical Research 14
Equity Offering 15
Rubius Therapeutics Raises USD277.3 Million in IPO of Shares 15
Rubius Therapeutics Inc – Key Competitors 16
Rubius Therapeutics Inc – Key Employees 17
Rubius Therapeutics Inc – Locations And Subsidiaries 18
Head Office 18
Recent Developments 19
Strategy And Business Planning 19
Sep 19, 2018: Raimondo, State officials break ground on new pharmaceutical manufacturing facility 19
Financial Announcements 20
Aug 31, 2018: Rubius Therapeutics announces second quarter 2018 financial results 20
Corporate Communications 21
Jun 06, 2018: Rubius Therapeutics Names Pablo J. Cagnoni As Chief Executive Officer 21
May 02, 2018: Rubius Therapeutics Appoints Jonathan R. Symonds to Board of Directors 22
Feb 20, 2018: Rubius Therapeutics Appoints Spencer Fisk as Senior Vice President of Manufacturing 23
Feb 01, 2018: Rubius Therapeutics Appoints Francis Cuss and Catherine Sohn to Board of Directors 24
Dec 14, 2017: Rubius Therapeutics Strengthens Leadership Team with Appointment of Andrew Oh as Chief Financial Officer 25
Sep 27, 2017: Rubius Therapeutics Appoints Chief Medical Officer; Other Key Leadership Team Hires 26
Aug 08, 2017: Cell therapy pioneer David Epstein expands role with Rubius Therapeutics to become executive chairman 27
Jan 04, 2017: Rubius Therapeutics Announces Appointment of Top Leadership 28
Legal and Regulatory 29
Sep 14, 2018: Rubius Therapeutics added to Russell 2000 and 3000 indexes 29
Appendix 30
Methodology 30
About GlobalData 30
Contact Us 30
Disclaimer 30

List of Tables
Rubius Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Rubius Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Rubius Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Rubius Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Rubius Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Rubius Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Rubius Therapeutics Raises USD100 Million in Venture Financing 10
Rubius Therapeutics Raises Funds through Venture Financing 11
Rubius Therapeutics Raises USD120 Million in Venture Financing 12
Rubius Therapeutics Raises USD25 Million in Venture Financing 13
Rubius Therapeutics Enters into Licensing Agreement with Whitehead Institute for Biomedical Research 14
Rubius Therapeutics Raises USD277.3 Million in IPO of Shares 15
Rubius Therapeutics Inc, Key Competitors 16
Rubius Therapeutics Inc, Key Employees 17

List of Figures
Rubius Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Rubius Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Rubius Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Rubius Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Rubius Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Rubius Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Rubius Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Rubius Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Rubius Therapeutics Inc (RUBY):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Innovent Biologics Inc (1801):製薬・医療:M&Aディール及び事業提携情報
    Summary Innovent Biologics Inc (Innovent Biologics) is a biopharmaceutical company that discovers, develops and manufactures monoclonal antibodies. The company offers monoclonal antibodies such as IBI301, IBI302 and IBI303, among others. Its products are used for the treatment of non-Hodgkin’s lymph …
  • Dr. Reddy’s Laboratories Ltd (DRREDDY):製薬・医療:M&Aディール及び事業提携情報
    Summary Dr. Reddy's Laboratories Ltd (Dr. Reddy's) is a pharmaceutical company which manufactures and markets generic formulations, active pharmaceutical ingredients, biosimilars and proprietary products. The company’s generic products are used for the treatment of conditions such as gastrointestina …
  • Alion Science and Technology Corporation:戦略・SWOT・企業財務分析
    Alion Science and Technology Corporation - Strategy, SWOT and Corporate Finance Report Summary Alion Science and Technology Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT …
  • Energy Transfer LP:企業の戦略・SWOT・財務分析
    Energy Transfer LP - Strategy, SWOT and Corporate Finance Report Summary Energy Transfer LP - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • CECO Environmental Corp (CECE):企業の財務・戦略的SWOT分析
    CECO Environmental Corp (CECE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • MAN Energy Solutions SE:企業の戦略的SWOT分析
    MAN Energy Solutions SE - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products an …
  • IKM Gruppen AS:石油・ガス:M&Aディール及び事業提携情報
    Summary IKM Gruppen AS (IKM Gruppen) is an oil and gas company. The company operates through its business divisions such as subsea completion and commissioning, electrical instrument and automation, engineering and operations, fabrication and inspection, and rig and downhole services. Its subsea com …
  • Symrise AG (SY1):企業の財務・戦略的SWOT分析
    Symrise AG (SY1) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Salvatore Ferragamo SpA (SFER):企業の財務・戦略的SWOT分析
    Salvatore Ferragamo SpA (SFER) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • REC Silicon ASA (REC)-エネルギー分野:企業M&A・提携分析
    Summary REC Silicon ASA (REC Silicon), formerly Renewable Energy Corporation ASA, produces and supplies advanced silicon materials. It offers solar grade polysilicon, electronic grade polysilicon, and silicon gases. Its products find application in the solar and electronics industries in the product …
  • Banco Bilbao Vizcaya Argentaria SA:戦略・SWOT・企業財務分析
    Banco Bilbao Vizcaya Argentaria SA - Strategy, SWOT and Corporate Finance Report Summary Banco Bilbao Vizcaya Argentaria SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, p …
  • ERI Bancaire SA:企業の戦略的SWOT分析
    ERI Bancaire SA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servic …
  • Delek Group Ltd:戦略・SWOT・企業財務分析
    Delek Group Ltd - Strategy, SWOT and Corporate Finance Report Summary Delek Group Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Tongaat Hulett Ltd (TON):企業の財務・戦略的SWOT分析
    Tongaat Hulett Ltd (TON) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Svenska Cellulosa AB:戦略・SWOT・企業財務分析
    Svenska Cellulosa AB - Strategy, SWOT and Corporate Finance Report Summary Svenska Cellulosa AB - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Univalor-製薬・医療分野:企業M&A・提携分析
    Summary Univalor is a university technology transfer organization which optimizes research outcomes by commercializing the technological innovations of researchers from academic institutions and health centers. The organization offers researcher services such as evaluating the technical feasibility …
  • Marinus Pharmaceuticals Inc (MRNS):企業の財務・戦略的SWOT分析
    Summary Marinus Pharmaceuticals Inc (Marinus Pharmaceuticals) is a biopharmaceutical company which discovers, develops and commercializes medicines for the treatment of epilepsy and other neuropsychiatric disorders. The company is evaluating its lead product candidate Ganaxolone, a gamma-aminobutyri …
  • Verastem Inc (VSTM):企業の財務・戦略的SWOT分析
    Summary Verastem Inc (Verastem) is a clinical-stage biopharmaceutical company with focus on the discovery, development and commercialization of drugs to treat cancer. The company’s lead product candidates include duvelisib, defactinib (VS-6063), FAK inhibitor (VS-4718) and PI3K/mTOR inhibitor (VS-55 …
  • Admedus Ltd (AHZ):製品パイプライン分析
    Summary Admedus Ltd (Admedus) develops, manufactures and distributes medical devices and technologies with focus on tissue engineering and immunotherapies. Using its proprietary ADAPT engineering process, the company is developing a group of regenerative tissue bio-scaffolds for use in soft tissue r …
  • Trafigura Group Pte Ltd:企業の戦略的SWOT分析
    Trafigura Group Pte Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products an …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆